to-BBB.com

About to-BBB.com

BBB Therapeutics, operating as a clinical-stage biotechnology firm, focuses on creating new treatments for severe brain conditions. The company was established in 2003 as a spin-off from the Netherlands Cancer Institute, with key individuals including Pieter Gaillard, a co-founder who also served as Chief Scientific Officer. Gaillard's background includes a Ph.D. in blood-brain barrier drug targeting from Leiden University, which directly informs the company's core scientific approach. Another significant figure in the company's history is Per-Olof Gunnerholm, who has held the position of CEO.

The core of the company's strategy is its proprietary G-Technology®, a platform designed to enhance the delivery of drugs across the blood-brain barrier (BBB). This biological gatekeeper is a significant hurdle in treating central nervous system diseases, as it often prevents therapeutic agents from reaching the brain. By attaching existing drugs to a glutathione-based liposome, the G-Technology® aims to shuttle these medicines into the brain more effectively. This approach serves pharmaceutical and biotechnology companies looking to improve their own drug candidates for brain disorders.

BBB Therapeutics' business model centers on the clinical development and subsequent commercialization of its drug candidates. The company's revenue generation would stem from milestones and royalties from licensing its products to larger pharmaceutical partners or through direct sales if it brings a product to market independently. The company has advanced its pipeline through various clinical trial phases. Its lead product, formerly known as 2B3-101, is a liposomal formulation of the chemotherapy drug doxorubicin aimed at treating brain tumors, including glioblastoma and brain metastases. Another product, 2B3-201, targeted neuroinflammatory conditions like multiple sclerosis. The company has secured funding from investors such as Aescap Venture and the Brain Tumor Fund to support its research and clinical trials.